MedTrace Logo

Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

NCT07546253 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-04-22

No results posted yet for this study

Summary

This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure diagnosis and treatment.

Conditions

  • Drug Resistant Epilepsy
  • Refractory Epilepsy

Interventions

OTHER

Participants are not assigned an intervention as part of the study.

For observational studies, participants are not assigned an intervention as part of the study.

Sponsors & Collaborators

  • NeuroOne Medical Technologies Corporation

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-07-31
Completion
2028-07-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07546253 on ClinicalTrials.gov